A FGFR1 inhibitor patent review: progress since 2010
| Autor: | Yinfeng Zhang, Peifeng Li, Kun Wang, Hong Xu, Jianxun Wang, Tao Yu, Murugavel Ponnusamy, Yan Liu, Yanyan Yang, Mengpeng Li |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Research groups Antineoplastic Agents Computational biology Pharmacology Patents as Topic 03 medical and health sciences 0302 clinical medicine Neoplasms Drug Discovery Medicine Animals Humans Molecular Targeted Therapy Receptor Fibroblast Growth Factor Type 1 Protein Kinase Inhibitors Drug discovery business.industry General Medicine Highly selective Clinical trial stomatognathic diseases 030104 developmental biology 030220 oncology & carcinogenesis Drug Design Molecular targets business Clinical evaluation |
| Zdroj: | Expert opinion on therapeutic patents. 27(4) |
| ISSN: | 1744-7674 |
| Popis: | FGFR1 is a well known molecular target for anticancer therapy. Many studies have proved that the regulation of FGFR1 activity is a promising therapeutic approach to treat a series of cancers. Therefore, the development of potent inhibitors has consequently become a key focus in the present drug discovery, and it is encouraging that several highly selective FGFR1 inhibitors have been identified from various sources in recent years. Areas covered: This article reviews patents and patent applications related to selective FGFR1 inhibitors published from 2010 to 2016. This summary highlights about 15 patents from different pharmaceutical companies and academic research groups. We used Baidu and NCBI search engines to find relevant patents as a search term. Expert opinion: In the past few years, considerable progress has been made in the identification and development of selective FGFR1 inhibitors in use. At present, at least 10 inhibitors of FGFR1 are in clinical trials, and several agents have shown encouraging results under experimental conditions. Given the fact that FGFR1 plays a crucial role in the regulation of cancer and other diseases, we hope that it will gain further attraction from pharmaceutical companies and encourage development of more novel, safe and efficient FGFR1 inhibitors in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|